DE60331933D1 - Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren - Google Patents

Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren

Info

Publication number: DE60331933D1
Authority: DE; Germany
Prior art keywords: cells; tumor; tumor cells; galactosyltransferase; alpha
Prior art date: 2002-10-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60331933T

Other languages

English (en)

Inventor

Charles J Link

Tatiana Seregina

Gabriela Rossi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Central Iowa Health System

Original Assignee

Central Iowa Health System

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-09

Filing date

2003-10-09

Publication date

2010-05-12

2003-10-09 Application filed by Central Iowa Health System filed Critical Central Iowa Health System

2010-05-12 Application granted granted Critical

2010-05-12 Publication of DE60331933D1 publication Critical patent/DE60331933D1/de

2023-10-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

210000004881 tumor cell Anatomy 0.000 title abstract 6
206010028980 Neoplasm Diseases 0.000 title abstract 3
230000003053 immunization Effects 0.000 title 1
238000002649 immunization Methods 0.000 title 1
210000004027 cell Anatomy 0.000 abstract 2
125000003169 alpha-Gal epitope group Chemical group [C@H]1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1O)CO)O[C@H]1[C@@H]([C@H](C(O[C@@H]1CO)*)NC(C)=O)O)O 0.000 abstract 1
230000030741 antigen processing and presentation Effects 0.000 abstract 1
210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
231100000433 cytotoxic Toxicity 0.000 abstract 1
230000001472 cytotoxic effect Effects 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 abstract 1
238000001415 gene therapy Methods 0.000 abstract 1
210000000987 immune system Anatomy 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000014207 opsonization Effects 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1
230000005909 tumor killing Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Environmental Sciences (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Engineering & Computer Science (AREA)
Biodiversity & Conservation Biology (AREA)
Oncology (AREA)
Animal Husbandry (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Developmental Biology & Embryology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DE60331933T 2002-10-09 2003-10-09 Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren Expired - Lifetime DE60331933D1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41734302P	2002-10-09	2002-10-09
PCT/US2003/032036 WO2004032865A2 (en)	2002-10-09	2003-10-09	Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase

Publications (1)

Publication Number	Publication Date
DE60331933D1 true DE60331933D1 (de)	2010-05-12

Family

ID=32094006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60331933T Expired - Lifetime DE60331933D1 (de)	2002-10-09	2003-10-09	Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren

Country Status (13)

Country	Link
US (5)	US20040191229A1 (de)
EP (1)	EP1549353B1 (de)
JP (1)	JP4966496B2 (de)
CN (2)	CN1756568A (de)
AT (1)	ATE462449T1 (de)
AU (1)	AU2003285863A1 (de)
CA (1)	CA2501744C (de)
DE (1)	DE60331933D1 (de)
DK (1)	DK1549353T3 (de)
ES (1)	ES2341335T3 (de)
HK (1)	HK1215044A1 (de)
MX (1)	MXPA05003705A (de)
WO (1)	WO2004032865A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2285832T3 (es)	1998-02-20	2007-11-16	Univ Miami	Complejo de peptido antigenico-proteina de choque termico modificada.
US20050201993A1 (en) *	2002-10-09	2005-09-15	Link Charles J.Jr.	Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
WO2004032865A2 (en)	2002-10-09	2004-04-22	Central Iowa Health System	Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
US20060140983A1 (en) *	2004-10-25	2006-06-29	Baylor Research Institute	Dendritic cells loaded with heat shocked melanoma cell bodies
US7820628B2 (en) *	2005-02-22	2010-10-26	University Of Massachusetts Medical School	Tumor lesion regression and conversion in situ into autologous tumor vaccines by compositions that result in anti-Gal antibody binding
US7713266B2 (en)	2005-05-20	2010-05-11	Myoscience, Inc.	Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7850683B2 (en) *	2005-05-20	2010-12-14	Myoscience, Inc.	Subdermal cryogenic remodeling of muscles, nerves, connective tissue, and/or adipose tissue (fat)
US7998486B2 (en)	2006-10-25	2011-08-16	Newlink Genetics Corporation	Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
US9254162B2 (en) *	2006-12-21	2016-02-09	Myoscience, Inc.	Dermal and transdermal cryogenic microprobe systems
US8409185B2 (en)	2007-02-16	2013-04-02	Myoscience, Inc.	Replaceable and/or easily removable needle systems for dermal and transdermal cryogenic remodeling
US20090004213A1 (en)	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
US8298216B2 (en) *	2007-11-14	2012-10-30	Myoscience, Inc.	Pain management using cryogenic remodeling
US20100112702A1 (en) *	2008-02-25	2010-05-06	Klein Benjamin Y	Method designed to divert glucose away from the glycolytic pathway
DK2257301T3 (da)	2008-03-03	2014-04-28	Univ Miami	Immunterapi baseret på allogene cancerceller.
AU2009226077B2 (en)	2008-03-20	2012-04-19	University Of Miami	Heat shock protein gp96 vaccination and methods of using same
CN102112150A (zh) *	2008-05-30	2011-06-29	格利科菲公司	用于生产具有末端α-1,3-连接的半乳糖的蛋白质的酵母菌株
US20110223196A1 (en) *	2008-11-21	2011-09-15	University Of Miami	Hiv/siv vaccines for the generation of mucosal and systemic immunity
WO2010075438A1 (en)	2008-12-22	2010-07-01	Myoscience, Inc.	Integrated cryosurgical system with refrigerant and electrical power source
WO2011059490A1 (en) *	2009-11-10	2011-05-19	Nestec S.A.	Heart aging biomarkers and methods of use
US20110150934A1 (en) *	2009-12-18	2011-06-23	University Of Notre Dame	Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
CN102917709B (zh)	2009-12-23	2018-04-24	格兰达利斯有限公司	弗林蛋白酶敲减和gm-csf增强的（fang）癌症疫苗
US9157084B2 (en) *	2009-12-23	2015-10-13	Gradalis, Inc.	Furin-knockdown bi-functional RNA
CN102711794B (zh) *	2010-01-04	2015-11-25	Kj生物科学有限公司	用于疫苗和诊断学的Dps融合蛋白
CN102286428A (zh) *	2011-06-04	2011-12-21	内蒙古医学院	一种在肿瘤细胞表面合成α-半乳糖苷表位并激活免疫细胞的方法
CN102716497A (zh) *	2011-07-07	2012-10-10	赵永祥	α1,3半乳糖基转移酶基因转染材料及其制备方法和应用
EP2802279B1 (de)	2012-01-13	2017-08-16	Myoscience, Inc.	Kryogene nadel mit gefrierzonenregelung
CA2860893A1 (en)	2012-01-13	2013-07-18	Myoscience, Inc.	Skin protection for subdermal cryogenic remodeling for cosmetic and other treatments
CA2861116A1 (en)	2012-01-13	2013-07-18	Myoscience, Inc.	Cryogenic probe filtration system
US9017318B2 (en)	2012-01-20	2015-04-28	Myoscience, Inc.	Cryogenic probe system and method
CN102760208B (zh) *	2012-07-03	2015-07-29	清华大学	基于模拟疫苗的动态人工免疫故障诊断方法
WO2014064534A2 (en)	2012-10-05	2014-05-01	Chrontech Pharma Ab	Injection needle, device, immunogenic compositions and method of use
US9295512B2 (en)	2013-03-15	2016-03-29	Myoscience, Inc.	Methods and devices for pain management
US9610112B2 (en)	2013-03-15	2017-04-04	Myoscience, Inc.	Cryogenic enhancement of joint function, alleviation of joint stiffness and/or alleviation of pain associated with osteoarthritis
WO2014146122A1 (en)	2013-03-15	2014-09-18	Myoscience, Inc.	Methods and systems for treatment of occipital neuralgia
WO2014151423A1 (en) *	2013-03-15	2014-09-25	Newlink Genetics Corporation	Carbohydrate-modified glycoproteins and uses thereof
EP2967706B1 (de)	2013-03-15	2021-09-08	Pacira CryoTech, Inc.	Stumpfe kryogene dissektionssonden
WO2014186596A2 (en) *	2013-05-15	2014-11-20	Newlink Genetics Corporation	Correlates of efficacy relating to tumor vaccines
EP3065658B1 (de)	2013-11-05	2021-03-31	Pacira CryoTech, Inc.	Sicheres kryochirurgisches behandlungssystem
KR20170109582A (ko)	2015-02-06	2017-09-29	히트 바이오로직스, 인코퍼레이티드	벡터 공동 발현 백신 및 공동 자극 분자
GB201505860D0 (en) *	2015-04-07	2015-05-20	Agalimmune Ltd	Therapeutic compositions and methods of use for treating cancer
US11311327B2 (en)	2016-05-13	2022-04-26	Pacira Cryotech, Inc.	Methods and systems for locating and treating nerves with cold therapy
CA3040123A1 (en)	2016-10-11	2018-04-19	University Of Miami	Vectors and vaccine cells for immunity against zika virus
CA3058938A1 (en)	2017-04-04	2018-10-11	Heat Biologics, Inc.	Intratumoral vaccination
US11896653B2 (en)	2017-09-13	2024-02-13	Unm Rainforest Innovations	Silicified cell replicas, methods of making, and methods of using
US11134998B2 (en)	2017-11-15	2021-10-05	Pacira Cryotech, Inc.	Integrated cold therapy and electrical stimulation systems for locating and treating nerves and associated methods
WO2021015584A1 (ko) *	2019-07-24	2021-01-28	주식회사 에스엘바이젠	불사화된 줄기세포주의 제조 방법 및 이의 용도
IL293446A (en)	2019-12-03	2022-07-01	Neuvogen Inc	Tumor cell vaccines
WO2021139810A1 (en) *	2020-01-10	2021-07-15	The University Of Hong Kong	Recombinant viruses expressing alpha-1, 3-galactosyltransferase and uses thereof
WO2021202449A1 (en) *	2020-03-30	2021-10-07	Unm Rainforest Innovations	Nanoparticle-loaded silicified cells, methods of making, and methods of use
WO2022256360A1 (en) *	2021-06-02	2022-12-08	Neuvogen, Inc.	Tumor cell vaccines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995024924A1 (en)	1994-03-15	1995-09-21	Medical College Of Pennsylvania And Hahnemann University	COMPOSITIONS AND METHODS FOR VACCINES COMPRISING α-GALACTOSYL EPITOPES
US6218166B1 (en) *	1994-12-09	2001-04-17	John Wayne Cancer Institute	Adjuvant incorporation into antigen carrying cells: compositions and methods
WO1998006746A2 (en) *	1996-08-16	1998-02-19	The Johns Hopkins University School Of Medicine	Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same
US5869035A (en) *	1996-11-13	1999-02-09	Human Gene Therapy Research Institute	Methods and compositions for inducing complement destruction of tissue
EP1119365A4 (de) *	1997-07-24	2003-08-13	Univ Jefferson	Zusammensetzung und methode zur verwendung von tumorzellen
US7005126B1 (en) *	1999-06-08	2006-02-28	Human Gene Therapy Research Institute	Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect
US7101543B2 (en) *	2000-03-31	2006-09-05	Novarx	Genetically modified cells expressing a TGFβ inhibitor, the cells being lung cancer cells
AU2002235141A1 (en) *	2000-11-27	2002-06-03	Geron Corporation	Glycosyltransferase vectors for treating cancer
WO2004032865A2 (en)	2002-10-09	2004-04-22	Central Iowa Health System	Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
US20050201993A1 (en) *	2002-10-09	2005-09-15	Link Charles J.Jr.	Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase

2003
- 2003-10-09 WO PCT/US2003/032036 patent/WO2004032865A2/en active Application Filing
- 2003-10-09 US US10/682,178 patent/US20040191229A1/en not_active Abandoned
- 2003-10-09 AT AT03779090T patent/ATE462449T1/de active
- 2003-10-09 CA CA2501744A patent/CA2501744C/en not_active Expired - Fee Related
- 2003-10-09 DK DK03779090.4T patent/DK1549353T3/da active
- 2003-10-09 EP EP03779090A patent/EP1549353B1/de not_active Expired - Lifetime
- 2003-10-09 DE DE60331933T patent/DE60331933D1/de not_active Expired - Lifetime
- 2003-10-09 CN CNA2003801011520A patent/CN1756568A/zh active Pending
- 2003-10-09 MX MXPA05003705A patent/MXPA05003705A/es active IP Right Grant
- 2003-10-09 ES ES03779090T patent/ES2341335T3/es not_active Expired - Lifetime
- 2003-10-09 JP JP2004543606A patent/JP4966496B2/ja not_active Expired - Fee Related
- 2003-10-09 CN CN201510381454.2A patent/CN104911210A/zh active Pending
- 2003-10-09 AU AU2003285863A patent/AU2003285863A1/en not_active Abandoned
2006
- 2006-09-19 US US11/533,184 patent/US7763461B2/en not_active Expired - Fee Related
- 2006-09-19 US US11/533,199 patent/US20070014775A1/en not_active Abandoned
2010
- 2010-09-09 US US12/878,756 patent/US8535658B2/en not_active Expired - Fee Related
2013
- 2013-08-14 US US13/966,446 patent/US9474801B2/en not_active Expired - Fee Related
2016
- 2016-03-14 HK HK16102936.5A patent/HK1215044A1/zh unknown

Also Published As

Publication number	Publication date
AU2003285863A1 (en)	2004-05-04
CA2501744A1 (en)	2004-04-22
US9474801B2 (en)	2016-10-25
US20110250233A1 (en)	2011-10-13
CN104911210A (zh)	2015-09-16
JP4966496B2 (ja)	2012-07-04
WO2004032865A9 (en)	2004-07-22
CA2501744C (en)	2012-01-03
WO2004032865A3 (en)	2004-06-10
WO2004032865A2 (en)	2004-04-22
JP2006507267A (ja)	2006-03-02
CN1756568A (zh)	2006-04-05
ES2341335T3 (es)	2010-06-18
EP1549353B1 (de)	2010-03-31
DK1549353T3 (da)	2010-07-12
US20070014775A1 (en)	2007-01-18
US20140037692A1 (en)	2014-02-06
ATE462449T1 (de)	2010-04-15
AU2003285863A8 (en)	2004-05-04
US20040191229A1 (en)	2004-09-30
EP1549353A2 (de)	2005-07-06
US8535658B2 (en)	2013-09-17
US20070014774A1 (en)	2007-01-18
MXPA05003705A (es)	2005-08-16
US7763461B2 (en)	2010-07-27
HK1215044A1 (zh)	2016-08-12

Legal Events

Date	Code	Title	Description
2011-04-21	8364	No opposition during term of opposition

Publication	Publication Date	Title
DE60331933D1 (de)	2010-05-12	Benutzung von alpha (1,3) -galactosyltransferase exprimierenden allogenen tumorzellen zur impfung gegen tumoren
YoungáKim et al.	2020	Adjuvant incorporated lipid nanoparticles for enhanced mRNA-mediated cancer immunotherapy
WO2008057235A3 (en)	2008-08-07	Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
IL176007A0 (en)	2006-10-05	Antibodies specific to c35 and pharmaceutical compositions containing the same
CN102149391A (zh)	2011-08-10	用于***疾病的组合物和方法
CN105899217A (zh)	2016-08-24	癌症疗法中的番木瓜花叶病毒和病毒样颗粒
Noh et al.	2014	GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity
Appelbe et al.	2017	Radiation-enhanced delivery of systemically administered amphiphilic-CpG oligodeoxynucleotide
CY1115407T1 (el)	2017-01-04	Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
DE69434244D1 (de)	2005-03-03	Verbesserte krebstherapie
Younes et al.	2021	Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity
Klimek et al.	2014	Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs
CN107847567A (zh)	2018-03-27	方法
DE60137146D1 (de)	2009-02-05	Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
CN105007930A (zh)	2015-10-28	用于治疗疾病的同种异体自噬体富集组合物
Macedo et al.	2016	Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles
CN106456730A (zh)	2017-02-22	用于诱导或延长细胞之细胞毒性免疫应答的方法的药物
Xie et al.	2023	The advances of adjuvants in mRNA vaccines
EP1556513A4 (de)	2007-03-14	Zusammensetzungen und verfahren zurbehandlung von krankheiten, die durch das humane papillomavirus vermitteltwerden
JP2009535298A5 (de)	2011-05-12
Park et al.	2020	A novel cancer immunotherapy utilizing autologous tumour tissue
Gupta et al.	2016	Periodontal vaccine: A new vista in periodontology-A review
Castiglione et al.	2005	Computational modeling of the immune response to tumor antigens
ES2968843T3 (es)	2024-05-14	Molécula de ARNm y agente fotosensibilizador para uso médico
Su et al.	2022	Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens